Document Type: Research Articles
Oncology Group, Gastroenterology Division, Medicine Department, Universidade Federal de Sao Paulo, São Paulo, Brazil.
Gastroenterology Division and Endoscopist, Universidade Federal de Sao Paulo, São Paulo, Brazil.
Surgery Department, Universidade Federal de Sao Paulo, São Paulo, Brazil.
Randox Laboratories Ltd., Crumlin, Co. Antrim, United Kingdom.
Background: Colorectal cancer (CRC) is one of the most frequent cancers. Genetic mutations in CRC already
described can be detected in feces. Microarray methods in feces can represent a new diagnostic tool for CRC and
significant improvement at public health. Aim: to analyze stool DNA by human DNA quantify and microarray
methods as alternatives to CRC screening. Method: Three methods were analyzed in stool samples: Human DNA
Quantify, RanplexCRC and KRAS/BRAF/PIK3CA (KBP) Arrays. Results: KBP array mutations were presented in
60.7% of CRC patients and RanplexCRC Array mutations in 61.1% of CRC patients. Sensitivity and specificity for
human DNA quantification was 66% and 82% respectively. Fecal KBP Array had 35% sensitivity and 96% specificity
and RanplexCRC Array method had 78% sensitivity and 100% specificity. Conclusion: Microarray methods showed
promise as potential biomarkers for CRC screening; however, these methods had to be optimized to improve accuracy
and applicability by clinical routine.